Search

Your search keyword '"Rafael Tourinho-Barbosa"' showing total 4 results
Start Over Author "Rafael Tourinho-Barbosa" Publisher sociedade brasileira de urologia
4 results on '"Rafael Tourinho-Barbosa"'

1. Available evidence on HIFU for focal treatment of prostate cancer: a systematic review

Author

Arnas Bakavicius, Giancarlo Marra, Petr Macek, Cary Robertson, Andre L. Abreu, Arvin K. George, Bernard Malavaud, Patrick Coloby, Pascal Rischmann, Marco Moschini, Ardeshir R. Rastinehad, Abhinav Sidana, Armando Stabile, Rafael Tourinho-Barbosa, Jean de la Rosette, Hashim Ahmed, Thomas Polascik, Xavier Cathelineau, and Rafael Sanchez-Salas

Subjects
Prostate cancer, familial [Supplementary Concept], High-Intensity Focused Ultrasound Ablation, Technology, complications [Subheading], Diseases of the genitourinary system. Urology, RC870-923
Abstract

ABSTRACT Purpose: Prostate cancer (PCa) is the second most common oncologic disease among men. Radical treatment with curative intent provides good oncological results for PCa survivors, although definitive therapy is associated with significant number of serious side-effects. In modern-era of medicine tissue-sparing techniques, such as focal HIFU, have been proposed for PCa patients in order to provide cancer control equivalent to the standard-of-care procedures while reducing morbidities and complications. The aim of this systematic review was to summarise the available evidence about focal HIFU therapy as a primary treatment for localized PCa. Material and methods: We conducted a comprehensive literature review of focal HIFU therapy in the MEDLINE database (PROSPERO: CRD42021235581). Articles published in the English language between 2010 and 2020 with more than 50 patients were included. Results: Clinically significant in-field recurrence and out-of-field progression were detected to 22% and 29% PCa patients, respectively. Higher ISUP grade group, more positive cores at biopsy and bilateral disease were identified as the main risk factors for disease recurrence. The most common strategy for recurrence management was definitive therapy. Six months after focal HIFU therapy 98% of patients were totally continent and 80% of patients retained sufficient erections for sexual intercourse. The majority of complications presented in the early postoperative period and were classified as low-grade. Conclusions: This review highlights that focal HIFU therapy appears to be a safe procedure, while short-term cancer control rate is encouraging. Though, second-line treatment or active surveillance seems to be necessary in a significant number of patients.

Published
2022
Full Text
View/download PDF

2. Biochemical recurrence after radical prostatectomy: what does it mean?

Author

Rafael Tourinho-Barbosa, Victor Srougi, Igor Nunes-Silva, Mohammed Baghdadi, Gregory Rembeyo, Sophie S. Eiffel, Eric Barret, Francois Rozet, Marc Galiano, Xavier Cathelineau, and Rafael Sanchez-Salas

Subjects
Prostatic Neoplasms, Prostate-Specific Antigen, Prostatectomy, Diseases of the genitourinary system. Urology, RC870-923
Abstract

ABSTRACT Background Radical prostatectomy (RP) has been used as the main primary treatment for prostate cancer (PCa) for many years with excellent oncologic results. However, approximately 20-40% of those patients has failed to RP and presented biochemical recurrence (BCR). Prostatic specific antigen (PSA) has been the pivotal tool for recurrence diagnosis, but there is no consensus about the best PSA threshold to define BCR until this moment. The natural history of BCR after surgical procedure is highly variable, but it is important to distinguish biochemical and clinical recurrence and to find the correct timing to start multimodal treatment strategy. Also, it is important to understand the role of each clinical and pathological feature of prostate cancer in BCR, progression to metastatic disease and cancer specific mortality (CSM). Review design A simple review was made in Medline for articles written in English language about biochemical recurrence after radical prostatectomy. Objective To provide an updated assessment of BCR definition, its meaning, PCa natural history after BCR and the weight of each clinical/pathological feature and risk group classifications in BCR, metastatic disease and CSM.

Full Text
View/download PDF

3. Biochemical recurrence after radical prostatectomy: what does it mean?

Author

Igor Nunes-Silva, Rafael Tourinho-Barbosa, Mohammed Baghdadi, Rafael Sanchez-Salas, Gregory Rembeyo, François Rozet, Eric Barret, Sophie S Eiffel, Victor Srougi, Xavier Cathelineau, and Marc Galiano

Subjects
Oncology, Biochemical recurrence, Male, medicine.medical_specialty, medicine.medical_treatment, 030232 urology & nephrology, Disease, Review Article, lcsh:RC870-923, Disease-Free Survival, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Risk Factors, Internal medicine, hemic and lymphatic diseases, Medicine, Humans, Pathological, Prostatectomy, business.industry, breakpoint cluster region, Prostatic Neoplasms, Prostate-Specific Antigen, medicine.disease, lcsh:Diseases of the genitourinary system. Urology, Radiation therapy, Prostate-specific antigen, 030220 oncology & carcinogenesis, Disease Progression, Neoplasm Recurrence, Local, business
Abstract

Background Radical prostatectomy (RP) has been used as the main primary treatment for prostate cancer (PCa) for many years with excellent oncologic results. However, approximately 20-40% of those patients has failed to RP and presented biochemical recurrence (BCR). Prostatic specific antigen (PSA) has been the pivotal tool for recurrence diagnosis, but there is no consensus about the best PSA threshold to define BCR until this moment. The natural history of BCR after surgical procedure is highly variable, but it is important to distinguish biochemical and clinical recurrence and to find the correct timing to start multimodal treatment strategy. Also, it is important to understand the role of each clinical and pathological feature of prostate cancer in BCR, progression to metastatic disease and cancer specific mortality (CSM). Review design A simple review was made in Medline for articles written in English language about biochemical recurrence after radical prostatectomy. Objective To provide an updated assessment of BCR definition, its meaning, PCa natural history after BCR and the weight of each clinical/pathological feature and risk group classifications in BCR, metastatic disease and CSM.

Published
2018

4. Prostate cancer in Brazil and Latin America: epidemiology and screening

Author

Antonio Carlos Lima Pompeo, Sidney Glina, and Rafael Tourinho-Barbosa

Subjects
Male, Gerontology, medicine.medical_specialty, Latin Americans, Epidemiology, Urology, Population, 030232 urology & nephrology, Developing country, Review Article, Global Health, lcsh:RC870-923, 03 medical and health sciences, Prostate cancer, Government Agencies, 0302 clinical medicine, Environmental health, medicine, Humans, Mass Screening, education, Developing Countries, Societies, Medical, education.field_of_study, business.industry, Health Policy, Incidence, Incidence (epidemiology), Public health, Prostatic Neoplasms, Prostate-Specific Antigen, medicine.disease, lcsh:Diseases of the genitourinary system. Urology, Early Diagnosis, Latin America, 030220 oncology & carcinogenesis, Life expectancy, business, Brazil
Abstract

Introduction: Prostate cancer is one of the tumors with higher incidence and mortality among men in the World. Epidemiological data are influenced by life expectancy of population, available diagnostic methods, correct collection of data and quality of health services. Screening of the disease is not standardized around the World. Up till now there is no consensus about the risks versus benefits of early detection. There are still missing data about this pathology in Latin America. Objective: to revise current epidemiologic situation and early diagnosis policies of prostate cancer in Brazil and Latin America. Materials and Methods: Medline, Cochrane Library and SciELO databases were reviewed on the subject of epidemiology and screening of prostate cancer. Screening research was performed in websites on national public health organizations and Latin America. Screening recommendations were obtained from those governmental organizations and from Latin American urological societies and compared to the most prominent regulatory agencies and societies of specialists and generalists from around the World. Results: Brazil and Latin America have a special position in relation to incidence and mortality of prostate cancer. In Brazil, it occupies the first position regarding incidence of cancer in men and the second cause of mortality. Central America has the highest rate of mortality of the continent with lower incidence/mortality ratios. Screening recommendations are very distinct, mainly among regulatory organs and urological societies. Conclusion: prostate cancer epidemiology is an important health public topic. Data collection related to incidence and mortality is still precarious, especially in less developed countries. It is necessary to follow-up long term screening studies results in order to conclude its benefits.

Catalog

Books, media, physical & digital resources
See catalog results